PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Indian Diabetes Market to Reach INR 6300 Crore by 2015 Finds IMARC Group - A new report expects the Indian diabetes market to grow exponentially in the coming years - IMARCgroup.com
Indian Diabetes Market to Reach INR 6300 Crore by 2015 Finds IMARC Group

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/04/23 - A new report expects the Indian diabetes market to grow exponentially in the coming years - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new report from IMARC Group entitled “Indian Diabetes Market Report & Outlook for 2010-2015” expects the Indian diabetes market to grow at a CAGR of 22% during 2011-2015 reaching revenues worth INR 6300 Crores. The report gives a comprehensive insight into the Indian diabetes market and serves as an excellent tool to understand not only the market trends, structure, drivers and restraints but also the outlook of the market till 2015. This report aims to serve as a statistical as well as an analytical guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into Indian diabetes market in some form or the other.

Report Highlights
• A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to INR 6300 Crores by 2015.
• In 2009, the market for Non-Insulin Anti-diabetics was worth INR 1377 Crores. This represented a highly fragmented market with USV being the leading player.
• USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market.
• IMARC Group expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.
• The Insulin Market was worth INR 527 Crores in 2009 with Abbott being the biggest player in this market.
• Sanofi Aventi’s Lantus (Insulin Glargine) represents one of the fastest growing drugs in the last five years.
• The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from the urban regions.

Forecasts: The report provides forecasts on:
• Number of diabetes patients
• Diagnosis and treatment rates in India
• Diabetes market
• Non-Insulin Anti-diabetics market
• Glitazones
• Biguanides
• Sulphonylureas
• Alpha-Glycosidase Inhibitors
• DPP-IV Inhibhitors
• GLP-1 Agonists
• Glinides
• All other Non-Insulin Anti-diabetic classes
• Insulin market

Competitive Landscape: This section covers:
• 2005-2009 sales and market shares of top players in the diabetes market
• 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
• 2005-2009 sales and market shares of top players in various Non-Insulin drug classes
• 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin drug classes
• 2005-2009 sales and market shares of top players in the Insulin market
• 2005-2009 sales of top drugs comprising the portfolio of key players in the Insulin market.

Key Questions Answered in this report
• What is the total size of the diabetes population in India and what are its characteristics?
• What are the diagnosis and drug treatment rates for diabetes in India?
• What are the key factors driving the growth of diabetes medication in India?
• What is the size and breakup of the total diabetes market in India?
• What is the size and breakup of the total Non-Insulin diabetes market in India?
• What is the size and breakup of the total Insulin market in India?
• Who are the key players in the Indian diabetes market and how have they performed?
• What is the outlook of the Indian diabetes market in the next five years?
• Which new products are expected to be launched in the next five years?
• Which therapy classes will show the highest growth in the next five years?
• What are the road blocks in the Indian diabetes market?

Table of Contents
1. EXECUTIVE SUMMARY

2. DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS

3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA
3.1 INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD.
3.2 INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 IMPROVING DIAGNOSIS AND TREATMENT RATES
3.4 LARGE UNTAPPED MARKET
3.5 BRIGHT OUTLOOK FOR INNOVATIVE DRUGS

4. THE INDIAN DIABETES EPIDEMIOLOGY
4.1 TOTAL PREVALENCE
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban and Rural Prevalence
4.1.3 Prevalence of Diabetes by Sex
4.1.4 Prevalence of Diabetes by Age Group
4.1.5 Prevalence of Diabetes in Various Regions in India
4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA

5. THE INDIAN DIABETES MARKET
5.1 MARKET TREND (2005-2009)
5.2 MARKET SEGMENTATION (2005-2009)
5.3 MARKET FORECASTS (2010-2015)

6. THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET
6.1 MARKET TREND (2005-2009)
6.2 COMPETITIVE LANDSCAPE (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
6.4 MARKET SEGMENTATION (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-Glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-IV Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.3 Market Forecasts (2010-2015)

7. THE INDIAN INSULIN MARKET
7.1 MARKET TREND (2005-2009)
7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
MARKET SEGMENTATION BY MODE OF ACTION
7.3 COMPETITIVE LANDSCAPE
7.3.1 Share of key Players
7.3.2 Portfolio of Key Players
7.4 MARKET FORECASTS (2010-2015)

8. ROAD BLOCKS
8.1 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS
8.2 PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES
8.3 HIGHLY FRAGMENTED AND ‘GENERICIZED’ MARKET
8.4 LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS

IMARC Group Asia
E: apac[.]imarcgroup.com - P: +91-120-425-6531

IMARC Group North America
E: america[.]imarcgroup.com - P: +1-631-791-1145

IMARC Group Europe, Middle East & Africa
E: ema[.]imarcgroup.com - P: +44-702-409-7331

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Indian Diabetes Market to Reach INR 6300 Crore by 2015 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)